Dawood Marwan, Sizopoulou Christina, Greenberger Shoshe, Barzilai Aviv, Pavlotsky Felix
Dr. Dawood is with the Rambam Health Care Campus in Haifa, Israel.
Drs. Sizopoulou, Greenberger, Barzilai, and Pavlotsky are with the Department of Dermatology at Sheba Medical Center in Tel Hashomer, Israel.
J Clin Aesthet Dermatol. 2022 Apr;15(4):31-35.
Narrowband UVB (NB UVB) has been suggested as an option for lichen planus control. However, the literature is lacking in reports of long-term results. We sought to evaluate the long-term results of NB UVB therapy in lichen planus.
This was a prospective, retrospective analysis of patients with lichen planus treated with NB UVB at our institution since 2004. The clinical response and relapse rate were recorded according to age, sex, mouth involvement, skin phototype, number of treatments, and total radiation dose.
One hundred thirty-seven of 192 (71%) eligible patients had a major response (MR) and 102 (74%) patients had no recurrence after an average follow-up period of 58.7 months. MR was achieved in 66 percent and 75 percent of men and women, respectively (=0.021) and 76 percent and 68 percent of patients with Fitzpatrick Skin Types I and II and Skin Types IV and V, respectively (=0.017). Age at the onset of the disease, number of treatments, and total UVB dose had no effect on the MR rate. The disease-free periods were 131 and 101 months for male and female patients, respectively (=0.06), and 128 and 103 months for patients 40 years or younger and older than 40 years of age, respectively (=0.07).
Based on our results, female patients and patients with lighter skin phototypes appeared to have higher MR rates. However, female and older patients appear to be at increased risk of recurrence.
窄谱中波紫外线(NB UVB)已被提议作为控制扁平苔藓的一种选择。然而,文献中缺乏长期结果的报道。我们试图评估NB UVB治疗扁平苔藓的长期结果。
这是一项对自2004年以来在我们机构接受NB UVB治疗的扁平苔藓患者进行的前瞻性、回顾性分析。根据年龄、性别、口腔受累情况、皮肤光类型、治疗次数和总辐射剂量记录临床反应和复发率。
192例符合条件的患者中有137例(71%)有主要反应(MR),平均随访58.7个月后,102例(74%)患者无复发。男性和女性分别有66%和75%达到MR(P=0.021),Fitzpatrick皮肤类型I和II以及皮肤类型IV和V的患者分别有76%和68%达到MR(P=0.017)。疾病发病年龄、治疗次数和总UVB剂量对MR率无影响。男性和女性患者的无病期分别为131个月和101个月(P=0.06),40岁及以下和40岁以上患者的无病期分别为128个月和103个月(P=0.07)。
根据我们的结果,女性患者和皮肤光类型较浅的患者似乎有更高的MR率。然而,女性和老年患者似乎复发风险增加。